GlycoEra AG
This profile has not been verified by the business owner.
Information may be incomplete or outdated.
#Glycoengineering
#Therapeutic product development
#Biopharmaceutical CMC development
Overview
GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.
Founded
2020
Employees
20-30
Keywords
#Glycoengineering
#Therapeutic product development
#Biopharmaceutical CMC development
Competitors in actively managing their profiles
These suggested companies are selected based on the characteristics of this profile
This is how your company profile looks to others.